FDA, AAMI Explore How To Consider Benefits, Risks In Postmarket

FDA has already put a lot of work into mapping out pathways for weighing benefit versus risk in premarket review decisions. Now the agency, with the help of the Association for the Advancement of Medical Instrumentation and industry, is trying to provide the same support for compliance and enforcement decisions.